observed that GLUT3-armored CAR T-cells demonstrated increased uptake of the glucose analog 2NBDG, greater release of effector cytokines, and enhanced tumor cell killing in vitro compared to GLUT1-armored CAR T-cells. Here, SLC2A1 is linked to neoplasm.